Clinical significance of B7-H6 protein expression in astrocytoma

@article{Guo2016ClinicalSO,
  title={Clinical significance of B7-H6 protein expression in astrocytoma},
  author={Jian-gui Guo and Cheng-cheng Guo and Zhenqiang He and Zhi-Gang Liu and Yang Wang and Yong-gao Mou},
  journal={OncoTargets and therapy},
  year={2016},
  volume={9},
  pages={3291 - 3297}
}
Currently, immunotherapy by blocking the immune checkpoint inhibitors, such as anti-PD-1, has been carried out in many clinical studies on recurrent glioma, and the preliminary results are satisfactory, which provides a rationale for the exploration of immune checkpoint inhibitors in glioma. B7-H6 is a newly discovered member of the B7 family, which triggers antitumor of natural killer cell cytotoxicity and cytokine secretion by binding the NKp30 receptor. B7-H6 mRNA and protein expressions… Expand
B7-H6 is a new potential biomarker and therapeutic target of T-lymphoblastic lymphoma.
  • Lei Yuan, Lu Sun, +5 authors X. Ke
  • Medicine
  • Annals of translational medicine
  • 2021
TLDR
Although the expression of B7-H6 varied across samples and did not correlate with patient survival, it was significantly associated with B symptoms, high ECOG scores, elevated serum lactate dehydrogenase level, and reduced complete remission at interim evaluation. Expand
High expression of B7-H6 in human glioma tissues promotes tumor progression
TLDR
This study identified that the B7-H6 knockdown in U87 and U251 glioma cells significantly suppressed cell proliferation, migration, invasion, and enhanced apoptosis along with induction of cell cycle arrest, suggesting that B7/H6 play an important role in the regulation of the biological behavior of these gliomas cells. Expand
Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer.
TLDR
The results of the present study revealed that higher B7-H6 expression level in breast cancer tissues was positively associated with tumor progression, indicating that B8 homolog 6 is associated with the progression and immunoevasion of human breast cancer; however, the molecular mechanisms underlying this potential effect require further investigation. Expand
Preferential Expression of B7-H6 in Glioma Stem-Like Cells Enhances Tumor Cell Proliferation via the c-Myc/RNMT Axis
TLDR
Functionally, knockdown of B7-H6 in GSLCs by siRNAs led to the inhibition of cell proliferation, with decrease in the expression of the oncogene Myc as well as inactivation of PI3K/Akt and ERK/MAPK signaling pathways. Expand
The prognostic value of B7-H6 in esophageal squamous cell carcinoma
TLDR
It is suggested that B7-H6 is widely expressed in ESCC samples and may represent a predictor of poor prognosis for ESCC. Expand
Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer
TLDR
An interaction between B7 molecules that contributes to a particular design of the inflammatory microenvironment may influence the efficiency of therapies based on antibodies blocking the PD-L1/PD1 pathway and can explain the detection of clinical benefits only in a fraction of patients treated with immune checkpoint inhibitors. Expand
The B7 Family Member B7-H6: a New Bane of Tumor
TLDR
The effectiveness of B7-H6 modified antitumor immunotherapy strategies had been verified in tumor-bearing mice, which opened a new door to targeted therapy, and this review will focus on the recent development on the roles of B 7-H 6 in tumor immunity, as well as mechanisms involved in the regulation of B8-H7 expression. Expand
B7-H6, an immunoligand for the natural killer cell activating receptor NKp30, reveals inhibitory effects on cell proliferation and migration, but not apoptosis, in cervical cancer derived-cell lines
TLDR
The results suggest that B7-H6 has an important, as of yet undescribed, role in the biology of the cervical tumor cells themselves, suggesting that this protein might be a promising target for anti-tumor therapy in the future. Expand
The prognostic value of B7‐H6 protein expression in human oral squamous cell carcinoma
  • Jiongke Wang, X. Jin, +7 authors Q. Chen
  • Medicine
  • Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • 2017
TLDR
The survival curves showed that B7-H6 was an independent prognostic factor of overall survival and disease-free survival in oral squamous cell carcinoma, and the recurrence, differentiation, and expression of B7 -H6 were related to the prognosis. Expand
New B7 Family Checkpoints in Human Cancers
  • L. Ni, C. Dong
  • Biology, Medicine
  • Molecular Cancer Therapeutics
  • 2017
TLDR
The aim of this article is to address the structure and expression of the new B7 family molecules as well as their roles in controlling and suppressing immune responses of T cells aswell as NK cells and the clinical significance and contribution of these checkpoint expressions in human cancers. Expand
...
1
2
...

References

SHOWING 1-10 OF 22 REFERENCES
B7-H6 Protein Expression has no Prognostic Significance in Human Gastric Carcinoma
TLDR
The data suggest that B7-H6, as detected by immunohistochemistry, is of limited value as a prognostic marker for gastric cancer. Expand
B7-H6 expression in non-small cell lung cancers.
TLDR
The study suggests that B7-H6 has a limited value as a prognostic marker in the patients of lung cancer, and no relevance was found for NKp30 expression in lung cancer tissues and non-tumor tissues. Expand
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy
TLDR
The contributions of B7- and CD28-family members in the context of cancer development are examined, the implications of current human findings in cancer immunotherapy are discussed, and recent evidence suggests that the presence of several B7 molecules may predict the responsiveness of immunotherapies that rely on pre-existing tumor-associated immune responses. Expand
The expression, function, and clinical relevance of B7 family members in cancer
TLDR
The blockade of negative signals mediated by the interaction of co-inhibitory ligands and counter-receptors of the B7 family is currently being studied as a potential immunotherapeutic strategy for the treatment of cancer in humans. Expand
The role of B7 family molecules in hematologic malignancy.
TLDR
Manipulation of the signals delivered by B7 ligands shows great potential in the treatment of cancers including leukemias and lymphomas and in regulating allogeneic T-cell responses after stem cell transplantation. Expand
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
TLDR
The identification of a tumor cell surface molecule that binds NKp30, a human receptor which triggers antitumor NK cell cytotoxicity and cytokine secretion is reported and this previously unannotated gene belongs to the B7 family and was designated B7-H6, emphasizing that the expression of stress-induced self-molecules associated with cell transformation serves as a mode of cell recognition in innate immunity. Expand
Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma
TLDR
This approach of T-cell activation or re-activation by immunological checkpoint inhibition holds the inherent promise to directly affect the tumor cell and thereby to potentially cure a subset of patients with mRCC. Expand
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
TLDR
Ipilimumab, an antibody targeting CTLA-4, appears to restore tumor immunity at the priming phase, whereas anti-PD-1/PD-L1 antibodies restore immune function in the tumor microenvironment, and antibody-based interventions targeting CTL antigen 4 and programmed cell death protein 1 produce significant anti-tumor activity with considerably less toxicity. Expand
Immune checkpoint inhibitors in advanced nonsmall cell lung cancer
TLDR
This review presents efficacy and toxicity results of the different immune checkpoint inhibitors (ICIs) currently developed in NSCLC and reports other checkpoints currently explored. Expand
Prospects of immune checkpoint modulators in the treatment of glioblastoma
TLDR
Challenges that need to be considered in the clinical development of drugs that target immune checkpoint pathways in glioblastoma, such as specific properties of the immune system in the CNS, issues with radiological response assessment, and potential interactions with established and emerging treatment strategies are discussed. Expand
...
1
2
3
...